This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS, MAPK pathways.
6 Primary · 6 Secondary · Reporting Duration: 2 years
Experimental Treatment
225 Total Participants · 3 Treatment Groups
Primary Treatment: Phase 1/1B Monotherapy · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: